Ashvin Ravi

Ashvin Ravi

Auto-generated profile, based on publicly available information

Ashvin Ravi

Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY 10029

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
MKMaria Koromina
Maria Koromina
ARAshvin Ravi
Ashvin Ravi
GPGeorgia Panagiotaropoulou
Georgia Panagiotaropoulou
BSBrian M. Schilder
Brian M. Schilder
JHJack Humphrey
Jack Humphrey
NMNiamh Mullins
Niamh Mullins
Bipolar disorder (BD) is a heritable mental illness with complex etiology. While the largest published genome-wide association study identified 64 BD risk loci, the causal SNPs and genes within these loci remain unknown. We applied a suite of statistical and functional fine-mapping methods to these loci, and prioritized 17 likely causal SNPs for BD. We mapped these SNPs to genes, and investigated their likely functional consequences by integrating variant annotations, brain cell-type epigenomic annotations, brain quantitative trait loci, and results from rare variant exome sequencing in BD. Convergent lines of evidence supported the roles of genes involved in neurotransmission and neurodevelopment including SCN2A, TRANK1, DCLK3, INSYN2B, SYNE1, THSD7A, CACNA1B, TUBBP5, PLCB3, PRDX5, KCNK4, CRTC3, AP001453 . 3, TRPT1, FKBP2, DNAJC4, RASGRP1, FURIN, FES, DPH1, GSDMB, MED24 and THRA in BD. These represent promising candidates for functional experiments to understand biological mechanisms and therapeutic potential. Additionally, we demonstrated that fine-mapping effect sizes can improve performance of BD polygenic risk scores across diverse populations, and present a high-throughput fine-mapping pipeline ( https://github.com/mkoromina/SAFFARI ).

15 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CLChia-Yi Joy Lee
Chia-Yi Joy Lee
ARAshvin Ravi
Ashvin Ravi
THTzu-Chieh Huang
Tzu-Chieh Huang
BWBriana Wyman
Briana Wyman
ZLZiyu Liu
Ziyu Liu
KBKristen J. Brennand
Kristen J. Brennand
Although defined by end-stage neuronal loss, neurodegenerative diseases are increasingly hypothesized to be initiated by early microglial dysfunction. Genetic risk for Alzheimer′s disease (AD) is particularly highly enriched for non-coding variants located in microglia-specific regulatory regions. Yet, the linkage-dense nature of these variants limits their functional interpretation. To elucidate how risk variants influence microglial gene regulation, we contrast fine-mapping of AD genome-wide association study (GWAS) loci by four complementary methods, and resolve a highly concordant set of putative causal variants. In total, 11,550 candidate regulatory sequences (CRSs), nominated from GWAS (n = 2,183), microglial expression quantitative trait loci (QTL) (n = 5,721) and microglial chromatin accessibility QTL (n = 1,519), are screened en masse by massively parallel reporter assay (MPRA) in human induced pluripotent stem cell (hiPSC)–derived microglia (iMGL) and immortalized HMC3 cell lines. Distinct sets of functional variants are identified between cellular models, underscoring the importance of using physiologically relevant microglia for variant interpretation. Functional regulatory variants (frVar) are enriched in promoters and splicing regions, with over half predicted to disrupt transcription factor (TF) binding. The affected TFs yield distinct regulatory modules, the first with an inflammatory program and the second with a DNA stress–response network. Mapping frVar to their predicted target genes reveals enrichment for biological processes related to amyloid biology, immune signaling, and neuron–microglia communication. Notably, we pinpoint functional variants within several understudied AD loci, including TSPOAP1, providing direct evidence for causal regulatory effects. Together, these findings establish the first large-scale microglial-context MPRA, define a microglial regulome underlying AD genetic risk, and provide a functional framework to refine noncoding variant interpretation and therapeutic target discovery.